Anktiva (nogapendekin alfa inbakicept-pmln)
ImmunGene · IL-15 Receptor Superagonist Complex
What is Anktiva? Anktiva (nogapendekin alfa inbakicept-pmln) is an IL-15 receptor superagonist complex used in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
About Anktiva
| Brand Name | Anktiva |
| Generic / INN | nogapendekin alfa inbakicept-pmln |
| Drug Class | IL-15 Receptor Superagonist Complex |
| Manufacturer | ImmunGene |
| Administration | Intravesical instillation |
| FDA Approval | 2024 |
| Presentation | Anktiva (nogapendekin alfa inbakicept-pmln) is supplied for intravesical use only. |
FDA-Approved Uses for Anktiva
The following indications are based on FDA approval as of the last review date. Your oncologist will determine appropriate use based on your specific cancer type, stage, biomarker status, and overall treatment plan.
- BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta or T1 papillary tumors, in combination with BCG
How Does Anktiva Work?
Anktiva is an IL-15 receptor superagonist complex that activates natural killer (NK) cells and CD8+ T cells by targeting the IL-15 receptor beta-gamma complex. When instilled directly into the bladder together with BCG, it enhances local immune activity against bladder tumor cells.
Dosage & Administration
Administered intravesically (directly into the bladder) in combination with BCG. Dosing schedule is determined by the treating urologist/oncologist. Not administered systemically (not an injection or infusion).
Dosing for oncology medications is individualized by the treating oncologist or oncology pharmacist. Do not adjust dosing without consulting your healthcare team. The information on this page is educational only and does not replace the official prescribing information or your provider's guidance.
Warnings, Precautions & Side Effects
General Warning
Intravesical administration only; do not administer intravenously. Monitor for systemic absorption and immune-related adverse reactions. Bladder irritation symptoms possible.
- BCG-related systemic infection if instilled with compromised urothelium
- Monitor for systemic immune activation
Common Side Effects
- Urinary urgency
- Urinary frequency
- Dysuria
- Hematuria
- Urinary tract infection
- Fatigue
- Nausea
This is not a complete list. Report any new or worsening symptoms to your oncologist or healthcare provider promptly.
Storage & Handling
Follow the prescribing information storage requirements. Consult the treating facility for handling protocols.
Oncology medications require careful handling. BiologicHealthPlus provides cold-chain specialty delivery with temperature monitoring for medications that require refrigeration. Do not use the medication if the storage chain has been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Anktiva is a specialty oncology medication covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage varies by plan, indication, and formulary tier. BiologicHealthPlus verifies benefits at no cost to patients.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Anktiva. Our team handles the full prior authorization process — submitting clinical documentation, peer-to-peer reviews when needed, and appeals — at no cost to patients or providers.
🏥 Medicare & Medicaid
Medicare coverage for oncology medications depends on route of administration. Intravenous oncology medications are typically covered under Medicare Part B (medical benefit) when administered in a clinical setting. Subcutaneous formulations may be covered under Part B or Part D depending on administration circumstances. Medicaid coverage varies by state.
🆓 Patient Assistance Programs
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. BiologicHealthPlus can assess your eligibility and help with the application process. Contact our team for a confidential eligibility review.
Prior Authorization Guide Patient Assistance Programs Insurance & Savings Medication Costs
Frequently Asked Questions About Anktiva
Anktiva (nogapendekin alfa inbakicept-pmln) is an IL-15 receptor superagonist approved by the FDA in 2024 for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, used in combination with BCG.
Anktiva is instilled directly into the bladder (intravesically), not given as an injection or IV. It is administered in combination with BCG by a urologist or oncology team.
BCG-unresponsive NMIBC means the bladder cancer has not responded adequately to prior BCG (Bacillus Calmette-Guérin) immunotherapy. Anktiva combined with BCG offers a treatment option for this difficult-to-treat patient population.
Coverage depends on your insurance plan. As a newer, specialized oncology agent, prior authorization is expected to be required. BiologicHealthPlus can assist with benefits verification.
Related Medications & Conditions
Related Medications
BCG (Bacillus Calmette-Guérin) · Gemcitabine · Mitomycin
Related Conditions
Non-muscle invasive bladder cancer (NMIBC) · Urothelial carcinoma · Carcinoma in situ (CIS)